• This MAGIC post hoc analysis evaluated CINV prevention efficacy and safety of APF530 versus ondansetron, each with fosaprepitant and dexamethasone, in patient subgroup receiving an anthracycline plus cyclophosphamide (AC) regimen. (nih.gov)
  • courses repeated at 28-day intervals) and VAC (vincristine 1.4 mg/m 2 every 3 weeks, anthracycline 30 mg/m 2 every 3 weeks, cyclophosphamide 400 mg/m 2 every 3 weeks) in patients with advanced metastatic breast cancer. (karger.com)
  • As a widely recognized standard regimen, R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is able to cure two-thirds patients with diffuse large B cell lymphoma (DLBCL), and t. (biomedcentral.com)
  • A combined analysis of two trials found that trastuzumab with adjuvant chemotherapy (doxorubicin, cyclophosphamide and paclitaxel) improved the relative risk of disease-free survival by 52% (HR 0.48, 95% CI 0.39 to 0.59), compared with multiple control groups receiving different chemotherapy regimens. (nps.org.au)
  • Determine whether intensification with anthracycline and cyclophosphamide improves disease-free survival in these patients. (knowcancer.com)
  • 85% for historical regimens (ie, cyclophosphamide/methotrexate/fluorouracil) are known to affect breast cancer survival. (jnccn.org)
  • Landmark meta-analyses by the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) initially showed a 20% to 25% relative risk reduction in breast cancer mortality for first-generation regimens (ie, cyclophosphamide/methotrexate/fluorouracil [CMF]) and increased benefit with the addition of anthracyclines and taxanes. (jnccn.org)
  • The results of our study showed that the type of chemotherapy called "anthracycline regimen" (which contains a drug called doxorubicin in combination with a drug called cyclophosphamide) was associated with a dramatic rise of granulocytic MDSC while other types chemotherapy did not. (databasefootball.com)
  • Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. (drugs.com)
  • Assess the antitumor activity of pemetrexed disodium in combination with gemcitabine in the treatment of women with metastatic breast cancer who have received an anthracycline and a taxane in the adjuvant and/or metastatic setting and no more than 1 chemotherapy regimen for metastatic disease (unless these were a taxane and anthracycline). (knowcancer.com)
  • Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. (who.int)
  • We investigated whether the use of ACEI/ARBs affects the clinical outcomes of primary breast cancer patients receiving taxane and anthracycline-based neoadjuvant chemotherapy. (jcancer.org)
  • Systemic adjuvant chemotherapy with anthracycline- and taxane-containing regimens has become the standard first line treatment for early and metastatic breast cancer [ 5 ], with large phase III randomized trials showing extremely high long-term disease-free survival and overall survival rates (resp. (hindawi.com)
  • Standard practice is to administer anthracycline-based chemotherapy followed by a taxane. (mendeley.com)
  • Selection criteria Randomised controlled trials comparing administering a taxane prior to an anthracycline with taxane following anthracycline to people with early breast cancer receiving chemotherapy. (mendeley.com)
  • This threshold, in addition to early versus late dose reductions, are poorly defined for third-generation anthracycline/taxane-based chemotherapy. (jnccn.org)
  • Prior therapy should have included an anthracycline and a taxane. (eisai.com)
  • Unless contraindicated, patients had to have received an anthracycline and/or a taxane in the neoadjuvant, adjuvant, and/or metastatic treatment setting. (ahdbonline.com)
  • Overall, 91% of patients in the talazoparib arm received previous taxane therapy, and 85% received an anthracycline. (ahdbonline.com)
  • Weekly nab-paclitaxel vs conventional paclitaxel or addition of carboplatin to anthracycline-taxane results in higher pCR rates with uncertain survival impact. (uni-koeln.de)
  • Metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel when further anthracycline therapy is not indicated (eg, prior cumulative doses of 400mg/m 2 of doxorubicin or its equivalents). (empr.com)
  • We evaluated carboplatin vs gemcitabine with a nab-paclitaxel backbone as a short 12-week A-free regimen with a focus on early response. (uni-koeln.de)
  • Conclusions: This first large randomized trial suggests high efficacy and excellent tolerability of a neoadjuvant nabpaclitaxel/carboplatin regimen, superior to nab-paclitaxel/gemcitabine in TNBC. (uni-koeln.de)
  • PURPOSE: To evaluate a triplet regimen combining immune checkpoint blockade, AKT pathway inhibition, and (nab-)paclitaxel as first-line therapy for locally advanced/metastatic triple-negative breast cancer (mTNBC). (bvsalud.org)
  • With docetaxel for metastatic breast cancer after failure of prior anthracycline-containing regimen. (empr.com)
  • Docetaxel-based chemotherapy regimens have substantially improved survival and recurrence rates for cancer patients. (hindawi.com)
  • Safety profile of docetaxel regimens includes toxicities, particularly a high risk of neutropenia and febrile neutropenia. (hindawi.com)
  • Granotax was a prospective, open label, multicentre, national phase IV study that evaluated the incidence and severity of neutropenia in adult patients with solid tumors being treated with a docetaxel-based regimen while receiving the GCSF lenograstim. (hindawi.com)
  • The low incidence of adverse effects and chemotherapy dose changes, delays, and withdrawals supports the use of lenograstim as effective primary prophylaxis in South African patients being treated with a docetaxel-based regimen. (hindawi.com)
  • G-CSFs have been shown to reduce overall mortality risk [ 8 , 11 ], reduce the incidence of other adverse events (grade 2 or greater anaemia, asthenia, anorexia, myalgia, nail disorders, and oral mucositis) associated with docetaxel-based chemotherapy regimens, and increase health related quality of life and consequently treatment compliance [ 8 , 12 ]. (hindawi.com)
  • Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. (drugs.com)
  • as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. (who.int)
  • In Brazil, Halaven was approved for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapy regimens for advanced disease. (eisai.com)
  • 2. As is the case with other anthracyclines the use of idarubicin Hydrochloride can cause myocardial toxicity leading to congestive heart failure. (nih.gov)
  • Cardiac toxicity is more common in patients who have received prior anthracyclines or who have pre-existing cardiac disease. (nih.gov)
  • Determine the toxicity of this regimen in this patient population. (knowcancer.com)
  • Both regimens were well tolerated with a low incidence of alopecia and serious nausea and vomiting, and there were no significant differences in toxicity. (karger.com)
  • MMM is an effective, well-tolerated regimen for advanced breast cancer, with toxicity similar to that of CMF and less than that of an anthracycline-contain-ing regimen. (karger.com)
  • After this the investigators adopted a 3 weeks on, 1 week off approach that resulted in less intense hematological toxicity compared with the weekly regimen. (medpagetoday.com)
  • The cumulative dose of anthracyclines is known to correlate with presence of toxicity. (medscape.com)
  • While smaller studies have looked at the utility of these commonly-used heart medications in guarding against anthracycline-induced cardiotoxicity, this trial is one of the first and the largest to date to test whether these drugs can prevent trastuzumab-related heart damage and prevent the need to discontinue a potentially life-saving treatment. (acc.org)
  • Adding panitumumab to a carboplatin-containing neoadjuvant chemotherapy regimen yielded a higher rate of pathologic complete response (pCR) in patients with triple-negative inflammatory breast cancer (IBC), a small study found. (medpagetoday.com)
  • Chemotherapy regimens containing anthracyclines, ifosfamide, or taxanes have been reported. (medscape.com)
  • Background Anthracyclines and taxanes are chemotherapeutic agents widely used in a sequential regimen in the adjuvant and neoadjuvant treatment of early breast cancer to reduce the risk of cancer recurrence. (mendeley.com)
  • Anthracyclines tend to be administered first as they were established before taxanes for treatment of early breast cancer. (mendeley.com)
  • Objectives To assess whether the sequence in which anthracyclines and taxanes are administered affects outcomes for people with early breast cancer receiving adjuvant or neoadjuvant therapy. (mendeley.com)
  • The incidence and severity was highest in patients receiving trastuzumab with anthracycline-containing chemotherapy regimens. (rxlist.com)
  • However, in patients who had received or were concurrently receiving anthracycline-based chemotherapy in addition to trastuzumab, the occurrence of heart damage was halved among those taking either the angiotensin converting enzyme inhibitor (ACE-inhibitor) lisinopril or beta blocker carvedilol, compared with placebo after two years of follow-up. (acc.org)
  • Our findings suggest that among women who are only on a standard course of trastuzumab neither carvedilol nor lisinopril seem to make a difference, but for those who had a history of being on anthracycline, these medications can be cardioprotective and should be considered," said Maya E. Guglin, MD, professor of medicine in the Division of Cardiovascular Disease, University of Kentucky, and lead author of the study. (acc.org)
  • Guglin explained that while anthracycline chemotherapy can cause long-lasting, potentially irreversible damage to the heart muscle, trastuzumab therapy has been associated with milder and often temporary declines in cardiac function. (acc.org)
  • Our data affirm that anthracyclines are aggressive agents that can cause damage to the heart muscle on a much greater scale than trastuzumab," she said, adding that the damage may already be done from prior exposure to this type of chemotherapy. (acc.org)
  • We also review the data the efficacy and safety of anthracycline-based and nonanthracycline-based adjuvant chemotherapy regimens combined with trastuzumab, and optimum chemotherapy regimens in small HER2-positive tumors. (carcinogenesis.com)
  • Until recently, acute myeloid leukemia (AML) patients used to have limited treatment options, depending solely on cytarabine + anthracycline (7 + 3) intensive chemotherapy and hypomethylating agents. (biomedcentral.com)
  • 1g/m 2 /day) cytarabine (HiDAC), continuous cytarabine plus an anthracycline (3+7), or HyperCVAD was considered high-intensity therapy. (confex.com)
  • With considerable advances in therapy, including the introduction of ATRA initially as a single agent and then in combination with anthracyclines, and more recently by development of arsenic trioxide (ATO)-containing regimens, APL is now characterized by complete remission rates of 90% and cure rates of ∼ 80%, even higher among low-risk patients. (nature.com)
  • Note that in regimens that contain a fluoropyrimidine (5-FU or capecitabine), infusional fluorouracil can be replaced by capecitabine. (medscape.com)
  • We have concluded that granulocytic MDSC levels increased during anthracycline chemotherapy regimen, but did not significantly differ between patients based on the pathologic complete response. (databasefootball.com)
  • Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. (semanticscholar.org)
  • 1-4 These survival gains have been attributed largely to advances in biological and genetic characterization of heterogeneous pediatric AML subtypes via next-generation sequencing with clinical outcome correlation, and to enhanced supportive care measures focused on reducing toxicities from intensive multi-agent chemotherapy regimens required for cure. (haematologica.org)
  • The approval was based on recently published clinical efficacy and safety data from the Phase 3, randomized, open-label, controlled study (ET743-SAR-3007), which evaluated YONDELIS versus the chemotherapy agent dacarbazine, in patients with unresectable or metastatic LPS or LMS previously treated with an anthracycline and at least one additional chemotherapy regimen. (prnewswire.com)
  • In fact, reducing the planned dose intensity of systemic adjuvant chemotherapy regimens by as little as 15% has been shown to significantly reduce time to progression and overall survival rates in women with metastatic breast cancer [ 5 ]. (hindawi.com)
  • 8 All patients had to have received no more than 3 previous cytotoxic chemotherapy regimens for locally advanced or metastatic breast cancer. (ahdbonline.com)
  • In 1973, daunorubicin (DNR) was shown to increase remission rates from 13 to 58% and to reduce hemorrhage-related mortality after 5 days of therapy relative to 6-MP-based regimens. (nature.com)
  • This staging system was used to select the appropriate treatment regimen: chemotherapy in combination with thoracic radiotherapy in patients with LS-SCLC, and chemotherapy alone in patients with ES-SCLC. (ersjournals.com)
  • Combination chemotherapy regimens are standard recommendations in the adjuvant setting. (medscape.com)
  • In general, combination chemotherapies are more likely to cause cancer patients to lose their hair than single-drug regimens. (realhealthmag.com)
  • Idarubicin Hydrochloride Injection, USP contains idarubicin hydrochloride and is a sterile, semi-synthetic, preservative-free solution (PFS) antineoplastic anthracycline for intravenous use. (nih.gov)
  • Based on this evidence, guidelines published by the American Society of Clinical Oncology and the European Organisation for Research and Treatment of Cancer state that when the overall risk of FN is 20% or greater, especially on "dose dense" regimens, primary prophylaxis with G-CSFs is justified [ 10 , 13 ]. (hindawi.com)
  • With the introduction of anthracycline-based regimens, 5-year survival rates have significantly improved in patients with early-stage breast cancer. (carcinogenesis.com)
  • Given the small numbers of patients with relapsed AML and historical logistical barriers to international collaboration including poor trial funding and drug availability, the management of AML relapse has varied among pediatric oncology cooperative groups with several salvage regimens utilized and a lack of universally defined response criteria. (haematologica.org)
  • Accordingly, a wide range of second complete remission (CR2) rates from 23% to 81% 5 , 6 and 5-year OS rates from 21% to 42% 7-1 1 has been reported across the spectrum of AML salvage regimens. (haematologica.org)
  • Using mouse models and human biospecimens, the investigators found that activation of cytosolic cyclic GMP-AMP synthase (cGAS)- and stimulator of interferon genes (STING)-dependent type 1 interferon signaling (cGAS-STING pathway) induced delayed cardiac inflammation after radiation and anthracycline chemotherapy. (mskcc.org)
  • Of those with advanced-stage KS, 140 (84%) were treated with cART plus liposomal anthracycline chemotherapy, 14 (8%) were treated with cART alone, 9 (5%) were treated with cART and radiotherapy for localized ulcerating tumors, and 3 (2%) were treated with cART plus complete excision. (medscape.com)
  • Chae YK, Brown EN, Lei X, Melhem-Bertrandt A, Giordano SH, Litton JK, Hortobagyi GN, Gonzalez-Angulo AM, Chavez-MacGregor M. Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes. (jcancer.org)
  • Again, several regimens are commonly used for consolidation therapy, including the European LeukemiaNet regimen, the European APL regimen, and the PETHEMA regimen. (medscape.com)
  • This Journal of Hematology & Oncology collection is the 2020 version of an annual series on emerging agents and regimens for cancer therapy. (biomedcentral.com)
  • For published articles in "Emerging agents and regimens for cancer therapy 2019," see here . (biomedcentral.com)
  • A recent re-evaluation of this regimen in Africa with multiple doses of intrathecal therapy compares favourably with recent studies of single agent CTX, and other drugs have been shown to be non-cross resistant. (hindawi.com)
  • For their study, they assigned patients with early-stage (T0) KS to combined antiretroviral (cART) therapy alone, and those with advanced-stage (T1) KS to cART plus liposomal anthracycline chemotherapy. (medscape.com)
  • Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. (drugs.com)
  • Oct. 23, 2015 /PRNewswire/ -- Janssen Biotech, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved YONDELIS ® (trabectedin) for the treatment of patients with unresectable (unable to be removed with surgery) or metastatic liposarcoma (LPS) or leiomyosarcoma (LMS) who received a prior anthracycline-containing regimen. (prnewswire.com)
  • Anthracyclines work by damaging the DNA in cancer cells and interfering with their ability to reproduce. (medicalnewstoday.com)
  • Doctors select anthracycline drugs based on the type of cancer cells they want to target and how potent they need to be. (medicalnewstoday.com)
  • The series, which is no longer open for submissions, will include research and review papers on novel agents, first-in-human clinical trials, and regimens for different cancer types. (biomedcentral.com)
  • The risk is cumulative, which means that the more anthracyclines a person receives, and the longer and more intense the treatment, the more their risk increases. (medicalnewstoday.com)
  • Determine time to progression and overall survival of these patients receiving this regimen. (knowcancer.com)
  • Determine whether rapid reduction in tumor volume by chest radiography and CT scan is predictive of improved outcome in patients treated with these regimens. (knowcancer.com)
  • However, in patients who were treated with anthracyclines, these heart medications were effective in preserving left ventricular ejection fraction-the heart's pumping ability. (acc.org)
  • In a Phase II study, MD Anderson researchers showed that a regimen of neoadjuvant and adjuvant treatment with checkpoint inhibitors nivolumab, a PD-1 inhibitor, and relatlimab, a LAG-3 inhibitor, was safe and effective in patients with resectable clinical stage III melanoma. (mdanderson.org)